Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $40.8182.

A number of research firms have recently commented on CAPR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. HC Wainwright increased their price target on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, December 3rd. B. Riley reaffirmed a “buy” rating and set a $50.00 price objective (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, Oppenheimer boosted their price target on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently made changes to their positions in CAPR. GoalVest Advisory LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $59,000. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the third quarter worth about $28,000. Parkside Financial Bank & Trust acquired a new stake in shares of Capricor Therapeutics during the third quarter worth approximately $36,000. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 4.8%

Shares of CAPR stock opened at $22.61 on Friday. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The company has a market capitalization of $1.03 billion, a P/E ratio of -12.56 and a beta of 0.22. The stock has a 50 day moving average of $22.98 and a two-hundred day moving average of $12.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting analysts’ consensus estimates of ($0.54). Sell-side analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.